Sumeet Ambarkhane

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell, Kami J. Maddocks, Eva González‐Barca et al. · Haematologica · 2021 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano et al. · Annals of Oncology · 2018 · 132 citations · Full text

Medicine, Hematology, Oncology +16

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the <scp>PREC</scp>i<scp>SE</scp> 3 study

William J. Sandborn, S. D. Lee, Charles Randall et al. · Alimentary Pharmacology & Therapeutics · 2014 · 74 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

Jean–Luc Van Laethem, Ivan Borbath, Hans Prenen et al. · The Lancet Oncology · 2024 · 49 citations · Full text

Medicine, Oncology, Pharmacology +11